Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | ACACA | Q13085 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308415 | 0.86 | ACACB (0.40) | ACACBACACAKMT2AHTTTSHR | |
| SCHEMBL309531 | 0.86 | CA12 (0.42) | ACACBACACAPTGS2CA12CA1 | |
| SCHEMBL309106 | 0.85 | HSD17B2 (0.44) | ACACBACACACA12CA1CA2 | |
| SCHEMBL26766443 | 0.80 | ACHE (0.36) | ACACBACACAKMT2A | |
| SCHEMBL308306 | 0.78 | PTGS2 (0.49) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL1501704 | 0.77 | ACACB (0.41) | ACACBACACAPTGS2TSHRPDE4A | |
| SCHEMBL308481 | 0.75 | CA12 (0.44) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL309739 | 0.73 | POLB (0.44) | KMT2AHTTTSHR | |
| SCHEMBL4782664 | 0.72 | TSHR (0.37) | HTTTSHR | |
| SCHEMBL309254 | 0.72 | CA12 (0.38) | PTGS2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102633-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3644998-B1 | NOVEL SPIROLACTONE COMPOUNDS | QUIXGEN INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230355609-A1 | Spirolactone Compounds | QUIXGEN, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| CN-110799187-B | Spirolactone compounds | 汇科锦公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11541046-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210145822-A1 | Novel Spirolactone Compounds | QUIXGEN, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3644998-A1 | NOVEL SPIROLACTONE COMPOUNDS | Quixgen, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| CN-110799187-A | Novel spirolactone compounds | 汇科锦公司 | 2020-02-14 | — | — | CN | disclosed |
| WO-2019006324-A1 | NOVEL SPIROLACTONE COMPOUNDS | QUIXGEN, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2111406-B1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK SHARP & DOHME (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8093389-B2 | e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases | MERCK SHARP & DOHME CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2111406-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | Merck & Co., Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008088688-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008088689-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171761-A1 | Substituted spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541046-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | ACACB 15/4885ACACA 1/4885PTGS2 1863/4885 |
| US-20210145822-A1 | Novel Spirolactone Compounds | ACACA, HSD17B10, AKR1C2 | ACACB 14/4885ACACA 1/4885PTGS2 1674/4885 |
| US-20230355609-A1 | Spirolactone Compounds | ACACA, AKR1C2, AKR1A1 | ACACB 15/4885ACACA 1/4885PTGS2 1863/4885 |
| US-12102633-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | ACACB 15/4885ACACA 1/4885PTGS2 1863/4885 |
| US-20080171761-A1 | Substituted spirochromanone derivatives | CBR3, CBR1, CNKSR1 | ACACB 713/4885ACACA 470/4885PTGS2 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.